MRI brain showed a new gadolinium-enhancing lesion at the left thalamus without vasogenic edema, a hyperintense T2/FLAIR lesion at the cortical gray matter of the parietal lobe, and scattered nodular leptomeningeal enhancement lesions (Fig. Immune Checkpoint Inhibitor-Associated Striatal Encephalitis Presenting with Subacute Progressive Parkinsonism Keywords: immune checkpoint inhibitor; striatal encephalitis; Atezolizumab; neurotoxicity; parkinsonism EN immune checkpoint inhibitor striatal encephalitis Atezolizumab neurotoxicity parkinsonism S7 S11 5 08/28/23 20230802 NES 230802 Atezolizumab, an immune checkpoint inhibitor (ICI) that targets programmed death ligand 1[1] has emerged as a novel immunotherapeutic agent approved for treating several cancers, but the expanding use of ICIs has led to an increase in neurological immune-related adverse events (irAEs) such as encephalitis (ICI-iE). [Extracted from the article]